Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Vaccines

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1747951

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1747951

Subunit Vaccines

PUBLISHED:
PAGES: 279 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Subunit Vaccines Market to Reach US$2.3 Billion by 2030

The global market for Subunit Vaccines estimated at US$1.3 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 10.1% over the analysis period 2024-2030. Protein Antigen, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$1.6 Billion by the end of the analysis period. Growth in the Polysaccharide Antigen segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$348.5 Million While China is Forecast to Grow at 13.9% CAGR

The Subunit Vaccines market in the U.S. is estimated at US$348.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$469.6 Million by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.1% and 8.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.0% CAGR.

Global “Subunit Vaccines” Market - Key Trends & Drivers Summarized

What Is Powering the Surge in Global Attention Toward Subunit Vaccines?

In recent years, the subunit vaccines market has emerged as one of the most critical segments of modern immunology, driven by a growing demand for safer, more targeted vaccination strategies. Unlike traditional vaccines that use whole pathogens-either weakened or inactivated-subunit vaccines contain only the essential antigens needed to stimulate an immune response, significantly reducing the risk of adverse effects. This characteristic has become increasingly vital amid rising concerns about vaccine safety and public resistance to conventional immunization methods. The COVID-19 pandemic brought unprecedented focus on vaccine platforms, propelling subunit vaccines into the spotlight due to their flexibility, relatively faster production cycles, and ease of modification for emerging variants. Global health authorities and governments have leaned towards these vaccines in their immunization strategies, particularly for diseases such as HPV, hepatitis B, pertussis, and more recently, COVID-19. Moreover, the scalability and stability of subunit vaccines offer logistical advantages, especially in low-resource settings where cold chain requirements pose a significant hurdle for traditional formulations.

How Is Technological Innovation Reshaping Vaccine Design and Delivery?

Cutting-edge advancements in molecular biology and protein engineering have revolutionized the development pipeline for subunit vaccines, leading to improved antigen selection and adjuvant pairing strategies. Recombinant DNA technology now allows for the precise identification and synthesis of immunodominant antigens, significantly enhancing the specificity and effectiveness of the resulting vaccines. Adjuvant systems like AS04 and MF59 have evolved to boost immunogenicity, thereby overcoming one of the longstanding challenges of subunit vaccines-suboptimal immune responses. Moreover, the integration of nanoparticle delivery platforms, lipid-based carriers, and virus-like particles (VLPs) has paved the way for improved antigen presentation and durability of immunity. Research institutions and pharmaceutical companies are also leveraging bioinformatics tools and artificial intelligence to simulate antigen behavior and optimize candidate selection, drastically reducing development timelines. These innovations not only increase efficacy but also broaden the applicability of subunit vaccines across demographics and geographies. As a result, a diverse pipeline of vaccines targeting complex pathogens such as HIV, malaria, and tuberculosis is currently in clinical trials, indicating a significant shift in vaccine design paradigms.

Are Policy and Regulatory Shifts Fostering a Favorable Ecosystem?

Policy frameworks and regulatory landscapes worldwide have adapted rapidly to accommodate the swift evolution of subunit vaccine technologies. Regulatory agencies like the FDA and EMA have implemented accelerated approval pathways and rolling review processes to ensure timely market access for promising vaccine candidates, especially during public health emergencies. Governments have launched several public-private partnerships, funding initiatives, and innovation hubs aimed at strengthening vaccine research infrastructure and manufacturing capacity. These efforts are evident in the rising number of technology transfer agreements and cross-border collaborations, particularly in regions like Asia-Pacific and Latin America, where vaccine equity has become a critical policy concern. Furthermore, the World Health Organization (WHO) and Gavi have emphasized subunit vaccines in global immunization agendas, ensuring supply chain prioritization and procurement incentives for developing nations. Additionally, the rising influence of non-governmental organizations (NGOs) and health alliances is driving coordinated efforts to integrate subunit vaccines into routine immunization schedules. These regulatory dynamics, coupled with increased public funding and harmonized clinical trial protocols, have created a fertile ground for innovation and rapid commercialization in the subunit vaccine market.

Why Are Subunit Vaccines Set for Rapid Market Expansion in the Coming Years?

The growth in the subunit vaccines market is driven by several factors rooted in technology evolution, expanding end-use cases, and shifting consumer behavior. On the technological front, breakthroughs in antigen discovery, protein expression systems, and recombinant technology are significantly enhancing the precision and scalability of vaccine production. Additionally, the integration of AI in predictive immunology and structure-based vaccine design is enabling the rapid development of highly specific formulations for emerging infectious diseases. On the end-use side, there is an increasing adoption of subunit vaccines across pediatric, adult, and geriatric populations due to their well-documented safety profile, especially in immunocompromised individuals. Hospitals and specialty clinics are increasingly including these vaccines in their preventive healthcare offerings, spurred by national vaccination programs and global health mandates. Consumer perception has also shifted favorably, with heightened awareness about vaccine safety and efficacy following the pandemic. Demand is surging not just in developed regions like North America and Europe but also in emerging markets, thanks to rising healthcare spending and improved vaccine distribution networks. Biopharmaceutical companies are responding by investing in dedicated manufacturing units and strategic mergers to capture market share. Collectively, these drivers underscore a robust growth trajectory for subunit vaccines in the global immunization landscape.

SCOPE OF STUDY:

The report analyzes the Subunit Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Protein Antigen, Polysaccharide Antigen); Disease (Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella, Other Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AIM Vaccine Co., Ltd.
  • AstraZeneca plc
  • Bavarian Nordic A/S
  • Bharat Biotech
  • Bio Farma
  • BioNTech SE
  • Curevo Vaccine
  • ExpreS2ion Biotechnologies
  • GlaxoSmithKline plc (GSK)
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Medigen Vaccine Biologics
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India
  • Shantha Biotechnics
  • SK Bioscience
  • VBI Vaccines Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP35835

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Subunit Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Shift Toward Safer Vaccine Platforms Propels Growth of Subunit Vaccine Market
    • Rising Incidence of Emerging Infectious Diseases Expands Addressable Market Opportunity
    • Increasing Public and Private R&D Investments Drives Innovation in Vaccine Delivery
    • Global Pandemic Preparedness Initiatives Strengthen Business Case for Scalable Vaccine Technologies
    • Advancements in Recombinant DNA Technology Spurs Development of Targeted Vaccines
    • Growing Focus on Personalized Vaccines Generates Demand for Subunit Formulations
    • Regulatory Push for Faster Approval Processes Supports Market Acceleration
    • Expansion of Pediatric and Geriatric Immunization Programs Sustains Market Growth
    • Greater Awareness of Vaccine Safety Drives Adoption of Subunit Vaccines
    • Increasing Partnerships Between Biotech and Pharma Drives Product Commercialization
    • Rising Demand for Thermostable Vaccines Enhances Development Efforts
    • WHO and GAVI-led Global Immunization Campaigns Drive Market Penetration
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Subunit Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Protein Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Protein Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Protein Antigen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polysaccharide Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polysaccharide Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polysaccharide Antigen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Infectious Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Infectious Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Diphtheria / Tetanus / Pertussis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Diphtheria / Tetanus / Pertussis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Diphtheria / Tetanus / Pertussis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for HPV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for HPV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Measles / Mumps / Rubella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Measles / Mumps / Rubella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Measles / Mumps / Rubella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • JAPAN
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • CHINA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • EUROPE
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Subunit Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • FRANCE
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • GERMANY
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Spain 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Russia 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Subunit Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Australia 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • INDIA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: India 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: South Korea 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Subunit Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Argentina 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Brazil 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Mexico 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Subunit Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Iran 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Israel 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: UAE 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030
  • AFRICA
    • Subunit Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Subunit Vaccines by Product Type - Protein Antigen and Polysaccharide Antigen Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Africa 15-Year Perspective for Subunit Vaccines by Product Type - Percentage Breakdown of Value Sales for Protein Antigen and Polysaccharide Antigen for the Years 2015, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Subunit Vaccines by Disease - Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Subunit Vaccines by Disease - Percentage Breakdown of Value Sales for Infectious Disease, Diphtheria / Tetanus / Pertussis, HPV, Measles / Mumps / Rubella and Other Diseases for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!